Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Jiang, Guiyang ^a   Fan, Chuifeng ^a   Zhang, Xiupeng ^a   Dong, Qianze ^a   Wang, Liang ^a   Liu, Yang ^a   Dai, Shundong ^a   Yang, Lianhe ^a   Zhang, Yong ^a   Yu, Juanhan ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY LABELING; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EGFR GENE; FEMALE; GENE MUTATION; GENETIC ALGORITHM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTEIN DETERMINATION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADULT; AGED; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84874835176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059183     Document Type: Article

References (26)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-46.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-8.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-57.
4. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-7.
5. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-501.
6. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, et al. (2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11: 2244-51.
7. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-20.
8. Mitsudomi T, Yatabe Y, (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-24.
9. Riely GJ, Politi KA, Miller VA, Pao W, (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-41.
10. Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, et al. (2008) Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 14: 4751-7.
11. Pao W, Ladanyi M, (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: 49-54-5.
12. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, et al. (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384.
13. Zhou C, Ni J, Zhao Y, Su B, (2006) Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. Cancer J 12: 33-39.
14. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, et al. (2006) High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97: 642-648.
15. Yu J, Kane S, Wu J, Benedettini E, Li D, et al. (2009) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15: 3023-3028.
16. Ambrosini-Spaltro A, Campanini N, Bortesi B, Azzoni C, Naldi N, et al. (2012) EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol 20 (4):: 356-62 doi:10.1097/PAI.0b013e31823e064b.
17. Brevet M, Arcila M, Ladanyi M, (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12 (2):: 169-76.
18. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y, (2010) Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 16 (13):: 3349-55.
19. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, et al. (2010) Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16 (12):: 3163-70.
20. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, et al. (2011) The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 73 (1):: 45-50.
21. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, et al. (2010) Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5 (10):: 1551-8.
22. Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, et al. (2011) Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 6 (8):: e23303.
23. Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, et al. (2012) A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer Oct 78 (1):: 39-44.
24. Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, et al. (2011) Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 74 (1):: 35-40.
25. Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, et al. (2010) Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 18 (8):: 135-42.
26. Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, et al. (2011) Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 179 (2):: 580-9.